Modality
Bispecific Ab
MOA
RAS(ON)i
Target
KRASG12C
Pathway
DDR
RSVMS
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
Sep 2019
→ Jul 2026
Phase 1Current
NCT04260818
761 pts·MS
2019-09→2026-07·Not yet recruiting
761 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-254mo awayInterim· MS
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Not yet…
Catalysts
Interim
2026-07-25 · 4mo away
MS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04260818 | Phase 1 | MS | Not yet recr... | 761 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |